Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Cell Surface Marker Expression in Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT03757065 Org: User:
Start: 06/12/19 End: 10/25/19 Due: 10/25/20

A Study of ALPN-303 in Adult Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05034484 Org: User:
Start: 11/15/21 End: 02/27/23 Due: 02/27/24

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04920383 Org: User:
Start: 06/22/21 End: 02/28/23 Due: 02/28/24

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04186637 Org: User:
Start: 06/02/20 End: 02/28/23 Due: 02/28/24

Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

Phase: N/A Priority: Normal
NCT ID: NCT03748836 Org: User:
Start: 01/29/19 End: 11/18/19 Due: 11/18/20

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias

Phase: N/A Priority: Normal
NCT ID: NCT05757570 Org: User:
Start: 07/03/23 End: 11/30/27 Due: 11/30/28

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Phase: N/A Priority: Normal
NCT ID: NCT05732402 Org: User:
Start: 03/15/23 End: 01/31/26 Due: 01/31/27

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT04835441 Org: User:
Start: 06/22/21 End: 07/09/24 Due: 07/09/25

ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD

Phase: N/A Priority: Normal
NCT ID: NCT04227938 Org: User:
Start: 05/11/20 End: 05/21/20 Due: 05/21/21